Determination of topotecan in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography

Biomedical Chromatography

Volumn 21, Issue 11, 2007, Pages 1191-1200

  de Vries, Nienke A ^a   Ouwehand, Mariët ^a   Buckle, Tessa ^a   Beijnen, Jos H ^a,b,c   van Tellingen, Olaf ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Mouse samples; Stability; Topotecan; Validation

Indexed keywords

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MAMMALS; PLASMA STABILITY; TISSUE;

DRUG ADMINISTRATION; HUMAN PLASMAS; MICE PLASMA; MOUSE SAMPLE; MOUSE TISSUES; PLASMA SAMPLES; REVERSED-PHASE HIGH PERFORMANCE; TISSUE HOMOGENATES; TOPOTECAN; VALIDATION;

PHARMACOKINETICS;

CARBON 14; TOPOTECAN;

ACCURACY; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CALIBRATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; DRUG MONITORING; ENVIRONMENTAL TEMPERATURE; FEMALE; FLUOROMETRY; FREEZING; HUMAN; MOUSE; NONHUMAN; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; THAWING; TISSUE HOMOGENATE;

MUS;

EID: 36749063882     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.874     Document Type: Article

References (26)

1. Bai F, Kirstein MN, Hanna SK, Iacono LC, Johnston B and Stewart CF. Determination of plasma topotecan and its metabolite N-desmethyl topotecan as both lactone and total form by reversed-phase liquid chromatography with fluorescence detection. Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences 2003; 784: 225-232.
2. Beijnen JH, Smith BR, Keijer WJ, van Gijn R, ten Bokkel Huinink WW, Vlasveld LT, Rodenhuis S and Underberg WJ. High-performance liquid chromatographic analysis of the new anti-tumour drug SK&F 104864-A (NSC 609699) in plasma. Journal of Pharmaceutical and Biomedical Analysis 1990; 8: 789-794.
3. Beran M, Estey E, O'Brien SM, Giles FJ, Koller CA. Kornblau S, Keating M and Kantarjian HM. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leukemia & Lymphoma 1998; 31: 521-531.
4. Chen J and Balthasar JP. High-performance liquid chromatographic assay for the determination of total and free topotecan in the presence and absence of anti-topotecan antibodies in mouse plasma. Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences 2005; 816: 183-192.
5. Friedman HS, Kerby T, Fields S, Zilisch JE, Graden D, McLendon RE, Houghton PJ, Arbuck S, Cokgor I and Friedman AH. Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke. Cancer 1999; 85: 1160-1165.
6. Grochow LB, Rowinsky EK, Johnson R, Ludeman S, Kaufmann SH, McCabe FL, Smith BR, Horowitz L, DeLisa A and Donehower RC. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metabolism and Disposition 1992; 20: 706-713.
7. Herben VM, Schoemaker E, Rosing H, van Zomeren DM, Bokkel Huinink WW, Dubbelman R, Hearn S, Schellens JH and Beijnen JH. Urinary and fecal excretion of topotecan in patients with malignant solid tumours. Cancer Chemotheraphy and Pharmacology 2002; 50: 59-64.
8. Hsiang YH, Hertzberg R, Hecht S and Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. The Journal of Biological Chemistry 1985; 260: 14873-14878.
9. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH and Schinkel AH. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. Journal of the National Cancer Institute 2000; 92: 1651-1656.
10. Kantarjian H. New developments in the treatment of acute myeloid leukemia: focus on topotecan. Seminars in Hematology 1999; 36: 16-25.
11. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annual Review of Biochemistry 1989; 58: 351-375.
12. Loos WJ, Stoter G, Verweij J and Schellens JH. Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine. Journal of Chromatography B Biomedical Applications 1996; 678: 309-315.
13. Loscher W and Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005; 2: 86-98.
14. Perez-Soler R. Topotecan in the treatment of non-small cell lung cancer. Seminars in Oncology 1997; 24: S20.
15. Recondo G, Abbruzzese J, Newman B, Newman R, Kuhn J, Hoff D von, Garteiz D and Raber M. A phase I trial of topotecan administered by a 24-hour infusion. Proceedings of the American Society for Cancer Research 1991; 32: 206.
16. Rosing H, Doyle E, Davies BE and Beijnen JH. High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma. Journal of Chromatography B Biomedical Applicationsl 1995; 668: 107-115.
17. Rosing H, Herben VM, van Gortel-van Zomeren DM, Hop E, Kettenes-van den Bosch JJ, ten Bokkel Huinink WW and Beijnen JH. Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan. Cancer Chemotheraphy and Pharmacology 1997; 39: 498-504.
18. Rosing H, van Zomeren DM, Doyle E, Bult A and Beijnen JH. O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan. Anticancer Drugs 1998; 9: 587-592.
19. Rosing H, van Zomeren DM, Doyle E, ten Bokkel Huinink WW, Schellens JH, Bult A and Beijnen JH. Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid chromatographic methods. Journal of Chromatography B Biomedical Science Applications 1999; 727: 191-203.
20. Stewart CF, Baker SD, Heideman RL, Jones D, Crom WR and Pratt CB. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. Journal of Clinical Oncology 1994; 12: 1946-1954.
21. ten Bokkel Huinink WW, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmstrom H, Coleman R, Fields SC and Heron JF. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. Journal of Clinical Oncology 1997; 15: 2183-2193.
22. Vali AM, Shafaghi B and Dadashzadeh S. Simple and sensitive high performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of topotecan in human plasma. Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences 2005; 818: 205-212.
23. van Warmerdam LJ, Verweij J, Schellens JH, Rosing H, Davies BE, Boer-Dennert M, Maes RA and Beijnen JH. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemotheraphy and Pharmacology 1995; 35: 237-245.
24. Verweij J, Lund B, Beijnen J, Planting A, Boer-Dennert M, Koier I, Rosing H and Hansen H. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Annals of Oncology 1993; 4: 673-678.
25. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer MC, Depierre A, Carmichael J, Krebs JB, Ross G, Lane SR and Gralla R. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. Journal of Clinical Oncology 1999; 17: 658-667.
26. Wall JG, Burris HA, III, Von Hoff DD, Rodriguez G, Kneuper-Hall R, Shaffer D, O'Rourke T, Brown T, Weiss G and Clark G. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anticancer Drugs 1992; 3: 337-345.